Dr. Nylander's research primarily centers on creating and testing new medications that target digestive conditions and inflammation. She studies how specific substances can impact stomach acid production, bile absorption, and the effectiveness of treatments for diseases such as duodenal ulcers and chronic diarrhea. For example, she has explored the effects of altering compounds similar to prostaglandins—natural substances in the body that help regulate various functions—on digestive processes. Her work aims to enhance the quality of life for patients suffering from bowel disorders and conditions like asthma where inflammation plays a critical role.
Key findings
In a study on bile acid absorption, 10 out of 20 patients with chronic diarrhea showed low bile acid retention, where treatment helped 8 of them find relief.
Her research on glucocorticosteroids found that a newly developed compound binds to the glucocorticoid receptor ten times faster than existing drugs, indicating potential for better treatment of inflammatory diseases.
One study demonstrated that a specific prostaglandin E2 analog significantly reduced stomach acid output in healthy men and patients with duodenal ulcers, which could lead to improved ulcer treatments.
Frequently asked questions
Does Dr. Nylander study digestive disorders?
Yes, Dr. Nylander conducts research focused on digestive disorders, including the effects of new medications on stomach acid production and bile absorption.
What treatments has Dr. Nylander researched?
She has researched treatments for conditions like chronic diarrhea and duodenal ulcers, particularly the effects of modified prostaglandins on digestion.
Is Dr. Nylander's work relevant to patients with inflammatory diseases?
Yes, her research on glucocorticosteroids has the potential to improve treatments for patients with inflammatory diseases, such as asthma and bowel conditions.
Publications in plain English
6 alpha-Fluoro- and 6 alpha,9 alpha-difluoro-11 beta,21-dihydroxy-16 alpha,17 alpha-propylmethylenedioxypregn-4-ene-3,20-dione: synthesis and evaluation of activity and kinetics of their C-22 epimers.
1998
Steroids
Thalén BA, Axelsson BI, Andersson PH, Brattsand RL, Nylander B +1 more
Plain English This study focused on creating new chemicals that could improve the effectiveness of glucocorticosteroids, medications commonly used to reduce inflammation. Researchers developed a specific compound that binds strongly to the glucocorticoid receptor in the body and found that it transforms in the body about ten times faster than a similar existing drug. This is important because it suggests that this new compound could provide better treatment for inflammatory diseases affecting the intestines and lungs.
Who this helps: Patients with inflammatory diseases like asthma or bowel conditions.
Radiological bile acid absorption test 75SeHCAT in patients with diarrhoea of unknown cause.
1996
Acta radiologica (Stockholm, Sweden : 1987)
Rudberg U, Nylander B
Plain English This study looked at a special test (the 75SeHCAT test) to understand bile acid absorption in 20 patients who had chronic diarrhea without a known cause. It found that 10 of these patients had low bile acid retention, and treatment with another medication helped 8 of them feel better. This is important because it shows that checking bile acid levels early on can help avoid unnecessary tests and improve patients' quality of life.
Who this helps: Patients with unexplained chronic diarrhea.
Effects of 16,16 dimethyl prostaglandin E2 on food-stimulated pancreatic secretion and output of bile in man.
1977
Scandinavian journal of gastroenterology
Ekelund K, Johansson C, Nylander B
Plain English This study looked at how a substance called 16,16 dimethyl prostaglandin E2 affects the pancreas and bile production when food is eaten. The researchers found that giving this substance to seven healthy people reduced the amount of digestive enzymes from the pancreas and bile produced, even though food moved through the stomach faster. This matters because it shows that this substance can impact digestion, which could have implications for how we understand or treat digestive issues.
Who this helps: Patients with digestive disorders.
Gastric secretory and motor inhibition induced by certain methyl analogues of prostaglandin E2 in healthy male volunteers and in patients with duodenal ulcer disease.
1976
Advances in prostaglandin and thromboxane research
Nylander B, Andersson S
Plain English This study looked at two specific compounds similar to a natural substance called prostaglandin E2 and how they affect stomach acid production in healthy men and patients with duodenal ulcers. The findings showed that these compounds can significantly reduce stomach acid output, but the effect was weaker in duodenal ulcer patients compared to healthy volunteers. Specifically, the 15-methyl compound was most effective, leading to notable decreases in acid secretion, which is important because it could help develop better treatments for ulcers.
Who this helps: This helps patients with duodenal ulcers and their doctors by offering potential new treatment options.
Gastric secretory inhibition by two 16-methylated analogs of prostaglandin E2 given intragastrically to patients with duodenal ulcer disease.
1975
Scandinavian journal of gastroenterology
Nylander B, Andersson S
Plain English This study looked at two modified versions of a substance called prostaglandin E2 and how they affect stomach acid and digestive enzyme production in patients with duodenal ulcers. The researchers found that both modified substances significantly reduced stomach acid production when given in doses of 140 micrograms, but not as much as seen in healthy individuals. This research is important because it may lead to better treatments for those suffering from ulcers by controlling stomach acid and digestion.
Who this helps: Patients with duodenal ulcers.
Effect of two methylated prostaglandin E2 analogs on gastroduodenal pressure in man.
1975
Scandinavian journal of gastroenterology
Nylander B, Andersson S
Plain English This study looked at the effects of two medications, which are modified versions of a substance called prostaglandin E2, on stomach and upper intestine movement in healthy men. They found that taking 140 micrograms of one type significantly reduced muscle activity in both the stomach and the first part of the intestine, while a lower dose (80 micrograms) had no effect. In contrast, the other medication given directly into the intestine at 80 micrograms immediately stopped its muscle activity. This research is significant because it helps us understand how these drugs might impact digestion and stomach acid production, which is important for developing treatments for digestive disorders.
Who this helps: Patients with digestive issues.
Effect of 16,16-dimethylPGE2 on gastric emptying and intestinal transit of a barium-food test meal in man.
1975
Scandinavian journal of gastroenterology
Nylander B, Mattsson O
Plain English Researchers studied the effects of a compound called 16,16-dimethyl PGE2 on how quickly food leaves the stomach and moves through the intestines in 8 healthy men. They found that taking this compound sped up stomach emptying in most of the volunteers and caused the food mixture to reach the colon faster. This is important because understanding how certain substances affect digestion can lead to better treatments for digestive disorders.
Who this helps: This helps patients with digestive issues.